Operose Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$696K Sell
2,741
-495
-15% -$115K 0.13% 81
2026
Q1
$791K Buy
3,236
+505
+18% +$118K 0.18% 63
2025
Q4
$565K Sell
2,731
-8
-0.3% -$1.58K 0.13% 81
2025
Q3
$508K Buy
2,739
+2
+0.1% +$343 0.13% 82
2025
Q2
$418K Sell
2,737
-110
-4% -$16.9K 0.12% 83
2025
Q1
$472K Sell
2,847
-474
-14% -$74.2K 0.16% 76
2024
Q4
$480K Sell
3,321
-1,633
-33% -$253K 0.16% 76
2024
Q3
$803K Buy
4,954
+507
+11% +$80.8K 0.26% 53
2024
Q2
$650K Buy
4,447
+150
+3% +$22.3K 0.23% 63
2024
Q1
$680K Buy
4,297
+2,366
+123% +$377K 0.23% 66
2023
Q4
$303K Sell
1,931
-720
-27% -$110K 0.12% 86
2023
Q3
$413K Buy
2,651
+1,426
+116% +$235K 0.16% 60
2023
Q2
$203K Hold
1,225
0.09% 83
2023
Q1
$190K Hold
1,225
0.09% 76
2022
Q4
$216K Hold
1,225
0.12% 62
2022
Q3
$200K Hold
1,225
0.13% 59
2022
Q2
$217K Buy
1,225
+1
+0.1% +$178 0.15% 54
2022
Q1
$217K Buy
1,224
+85
+7% +$14.5K 0.15% 64
2021
Q4
$195K Buy
+1,139
New +$186K 0.16% 60

Other funds holding JNJ

Operose Advisors's JNJ Position: Q2 2026 in Review

Operose Advisors reduced its Johnson & Johnson (JNJ) stake by 15% in Q2 2026, selling an estimated $115K and leaving 2,741 shares worth $696K. The position accounts for 0.13% of the portfolio, ranked #81.

Operose Advisors first reported a position in JNJ in Q4 2021 and has held it in 19 quarters since. The position peaked at $803K in Q3 2024. 4,665 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Operose Advisors held 2,741 shares of Johnson & Johnson worth $696K as of Q2 2026.
  • Operose Advisors sold 495 Johnson & Johnson shares in Q2 2026, an estimated $115K.
  • Johnson & Johnson made up 0.13% of Operose Advisors's portfolio in Q2 2026, its #81 holding.
  • Operose Advisors first reported a position in Johnson & Johnson in Q4 2021 and has held it in 19 quarters since.
  • Operose Advisors's Johnson & Johnson position peaked at $803K in Q3 2024.
  • 4,665 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.